Michelle T. Long, MD, MSc
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Preventive Medicine & Epidemiology

MD, Tufts University School of Medicine
MSc, Boston University School of Public Health
BA, Middlebury College

Pronouns: she/her/hers



Michelle T. Long, MD, MSc is a physician-scientist with an expertise in Nonalcoholic fatty liver disease (NAFLD), and an Associate Professor of Medicine at Boston University. She completed her clinical training at Massachusetts General Hospital and Boston Medical Center. Dr. Long is the Director of the NAFLD Research Center and the Director of Clinical Research for the Section of Gastroenterology and Hepatology. Her clinical and research interests center on the relationship between NAFLD and cardiovascular disease. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD and in imaging and risk stratification strategies for hepatic fibrosis. Dr. Long has projects at Boston Medical Center and at the Framingham Heart Study where she is the PI of a study evaluating the prevalence and risk factors for liver fat (steatosis) and fibrosis. In Framingham, she is investigating the clinical and genetic correlates of hepatic steatosis and fibrosis as measured by transient elastography. Dr. Long receives research funding from the NIH (NIDDK), Doris Duke Charitable Foundation, Gilead Sciences, Echosens Corporation, and Boston University. She has expertise in epidemiology, visceral fat, liver imaging including computed tomography, ultrasound, and transient elastography. Dr. Long is also a clinical hepatologist and endoscopist.

Dr. Long is additionally interested in novel therapeutics for NAFLD and Non-alcoholic steatohepatitis (NASH) and runs the clinical trials program for the NAFLD Research Center.

Her other research interests include alcohol-related liver disease, hepatitis C, outcomes in end-stage liver disease/cirrhosis.

Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Gastroenterology

Investigator
Framingham Heart Study


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Full Member
Boston University Medical Center
Boston Nutrition Obesity Research Center




Resting metabolic signature of non-alcoholic fatty liver disease and the metabolic response to acute exercise in a community based sample
07/01/2019 - 08/05/2022 (PI)
Doris Duke Charitable Foundation


Prevalence and risk factors for hepatic steatosis and fibrosis as measured by transient elastography
03/15/2016 - 05/31/2019 (PI)
Echosens



NATiV3: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stag
05/17/2022 - 05/17/2029 (PI)
Inventiva S.A.

Global Longitudinal Assessment of Nonalcoholic Fatty Liver Disease (NAFLD) using Magnetic Resonance Elastography GOLD-MINE Study Protocol
06/15/2020 - 08/03/2027 (Multi-PI)
PI: Michelle T. Long, MD, MSc
The Regents of the University of Calif., U.C. San Diego Astrazeneca Pharm

A Phase 1, Double Blind, Randomised, Placebo-controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients with Non-alcoholic Steatohepatitis (NASH) with Fibrosis S
12/01/2021 - 11/30/2024 (PI)
Astrazeneca Pharmaceuticals

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic
09/08/2020 - 07/31/2023 (PI)
Terns Pharmaceuticals, Inc.

AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
07/01/2019 - 07/31/2023 (PI)
Allergan Sales, LLC

MB130-068
12/06/2018 - 03/31/2023 (PI)
Bristol-Myers Squibb Company

Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis
01/15/2020 - 01/14/2023 (PI)
Celgene

Identifying clinical and genetic correlates of hepatic fibrosis from fatty liver disease in the…
01/12/2018 - 08/05/2022 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
5K23DK113252-03

Determining the burden, heritability, and clinical implications of increased liver stiffness from…
01/02/2019 - 12/31/2021 (PI)
Gilead Sciences

MB130-069
12/06/2018 - 12/06/2021 (PI)
Bristol-Myers Squibb Company

Showing 10 of 11 results. Show All Results

Title

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Florea VV, Gajjar P, Huang S, Tang J, Zhao S, Davenport M, Mi MY, Haff M, Zhang X, Miller PE, Vasan RS, Liu CT, Lewis GD, Shah RV, Long MT, Nayor M. Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community. Liver Int. 2025 Jan; 45(1):e16147.View Related Profiles. PMID: 39673712; PMCID: PMC11649011; DOI: 10.1111/liv.16147;
     
  2. Yiannakou I, Long MT, Jacques PF, Beiser A, Pickering RT, Moore LL. Eggs, Dietary Choline, and Nonalcoholic Fatty Liver Disease in the Framingham Heart Study. J Nutr. 2024 Oct 16.View Related Profiles. PMID: 39424072
     
  3. Alanaeme CJ, Ghazi L, Akinyelure OP, Wen Y, Christenson A, Poudel B, Dooley EE, Chen L, Hardy ST, Foti K, Bowling CB, Long MT, Colantonio LD, Muntner P. Trends in the Prevalence of Multiple Chronic Conditions Among US Adults With Hypertension From 1999-2000 Through 2017-2020. Am J Hypertens. 2024 Jun 14; 37(7):493-502. PMID: 38576398; PMCID: PMC11519032; DOI: 10.1093/ajh/hpae040;
     
  4. Sun N, Prescott B, Ma J, Mohanty A, Long MT, Walker ME. Prevalence of Steatotic Liver Disease Subtypes and Association With Metabolic Risk Factors in the Framingham Heart Study. Clin Gastroenterol Hepatol. 2024 Nov; 22(11):2330-2333.View Related Profiles. PMID: 38857746
     
  5. Niezen S, Goyes D, Vipani A, Yang JD, Ayoub WS, Kuo A, Long MT, Trivedi HD. Food Insecurity in Hispanic Populations Is Associated with an Increased Risk of Hepatic Steatosis: A Nationally Representative Study. J Clin Med. 2024 May 29; 13(11). PMID: 38892917; PMCID: PMC11173297; DOI: 10.3390/jcm13113206;
     
  6. Cooper LL, Prescott BR, Xanthakis V, Benjamin EJ, Vasan RS, Hamburg NM, Long MT, Mitchell GF. Association of Aortic Stiffness and Pressure Pulsatility With Noninvasive Estimates of Hepatic Steatosis and Fibrosis: The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2024 Jul; 44(7):1704-1715.View Related Profiles. PMID: 38752348; PMCID: PMC11209780; DOI: 10.1161/ATVBAHA.123.320553;
     
  7. Fantasia KL, Austad K, Mohanty A, Long MT, Walkey A, Drainoni ML. Safety-Net Primary Care and Endocrinology Clinicians' Knowledge and Perspectives on Screening for Nonalcoholic Fatty Liver Disease: A Mixed-Methods Evaluation. Endocr Pract. 2024 Mar; 30(3):270-277.View Related Profiles. PMID: 38184239
     
  8. Altajar S, Wang N, Rosenthaler MP, Murabito JM, Long MT. NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study. J Clin Med. 2023 Dec 06; 12(24).View Related Profiles. PMID: 38137592; PMCID: PMC10743412; DOI: 10.3390/jcm12247523;
     
  9. Dichtel LE, Corey KE, Haines MS, Chicote ML, Lee H, Kimball A, Colling C, Simon TG, Long MT, Husseini J, Bredella MA, Miller KK. Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2023 Nov 17; 108(12):e1542-e1550. PMID: 37379033; PMCID: PMC10655511; DOI: 10.1210/clinem/dgad375;
     
  10. Donovan K, Thomas OW, Sweeney T, Ryan TJ, Kytomaa S, Zhao M, Zhong W, Long M, Rajendran I, Sarfaty S, Lenders C. Eat to Treat: The Methods and Assessments of a Culinary Medicine Seminar for Future Physicians and Practicing Clinicians. Nutrients. 2023 Nov 17; 15(22).View Related Profiles. PMID: 38004212; PMCID: PMC10674360; DOI: 10.3390/nu15224819;
     
Showing 10 of 95 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 94 publications over 12 distinct years, with a maximum of 14 publications in 2023

YearPublications
20071
20155
20166
20178
20188
201913
202010
202111
202211
202314
20246
20251

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

Is Fatty Liver Disease a Risk Factor for Cardiovascular Disease?

Hep 8/4/2023

Even Non-heavy Drinking May Lead to Liver Problems, Says New Study

Yahoo 12/20/2022

Even Non-heavy Drinking May Lead to Liver Problems, Says New Study

Eat this, not that 12/20/2022

Study finds non-heavy alcohol use associated with liver fibrosis

Medical Xpress 12/8/2022

Not the Usual Suspects: Don't Overlook NAFLD in Lean Patients

Medscape 8/30/2022

New Update Focuses on NAFLD in Lean People

Medscape 7/26/2022

New update focuses on NAFLD in lean people

MDedge 7/26/2022

Mixed Bag for Semaglutide in NASH-Related Compensated Cirrhosis

MedPage Today 6/27/2022

Fatigue Tied to Worse Outcomes in Patients With NASH

MedPage Today 5/9/2022

Adding Mesalamine to Corticosteroids Showed No Benefit in Patients With Severe UC

Medpage Today 4/13/2022

Study Supports Expanded Use of HCV-Infected Liver Donation

Medpage Today 4/11/2022

Review Highlights Unmet Need for More Effective Therapies in Crohn's

Medpage Today 3/16/2022

Drinking These Popular Beverages More Than Doubles Your Risk for Fatty Liver Disease

Woman's World 11/30/2021

The #1 Worst Drink for Your Liver, New Study Says

Eat This, Not That! 11/14/2021

Pan-PPAR Agonist 'Promising' for NASH Patients

MedPage Today 10/20/2021

9 Actionable Ways to Support Gender Equity in Gastroenterology

HealthCity 9/29/2021

Removing Opioids From the PASS Will Be Beneficial

Medpage Today 9/27/2021

Herbal Weight-Loss Supplement Tied to Severe Liver Damage

MedPage Today 8/17/2021

Medical Campus Promotes 13 Faculty to Associate Professor

BU Today 7/30/2021

FAST Score Can Stratify NASH Risk in Diabetics

Gastroenterology & Endoscopy News 5/25/2021

Boston Medical Center Receives Support from Gilead Sciences to Improve Care for High-Risk Patients Living with Non-Alcoholic Fatty Liver Disease

Mobile Health Times 1/12/2021

Obese Patients With NAFLD May Have Lower Cirrhosis Risk After Bariatric Surgery

Medscape 4/13/2020

Obese Patients with NAFLD May Have Lower Cirrhosis Risk after Bariatric Surgery

MD Alert 4/11/2020

NAFLD Fibrosis Confirmed to Predict Poor Outcome

MedPage Today 2/7/2020

Alcohol Use Increases Risk for Clinically Defined NAFLD

Healio 12/11/2019

Concord Doctor Receives Doris Duke Clinical Scientist Development Award

Wicked Local Concord 7/22/2019

2020 Boston University School of Medicine: Resident Research Mentor Award
2019 NASH TAG Conference: Emerging Leader in NAFLD
2016 Boston University School of Medicine: Women's Leadership Conference Selected Participant
2016 Boston University School of Medicine: Faculty Development and Diversity Grant Recipient
2015-2020 Boston University School of Medicine: NIH Loan Repayment Program Recipient
2014 Boston University School of Medicine: 3rd Place, Evans Research Day
2009 Tufts University School of Medicine: Massachusetts Medical Society Scholars Award
2009 Tufts University School of Medicine: Glasgow-Rubin Citation for Academic Achievement
2009 Tufts University School of Medicine: Phi Delta Epsilon Fraternity Award
2009 Tufts University School of Medicine: Alpha Omega Alpha
2008 Tufts University School of Medicine: Magna cum laude Scientific electronic exhibit award
2008 Tufts University School of Medicine: Ada Draper, MD Scholarship
2006-2007 Tufts University School of Medicine: Boston Albert Schweitzer Fellowship
2006-2008 Tufts University School of Medicine: USA Funds Scholarship
2004 Middlebury College: Magna cum laude

Dr. Long mentors Fellows, PhD Candidates, Residents, Medical Students and Undergraduate Students.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

85 E. Concord St
Boston MA 02118
Google Map


Long's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department